N-Glycoproteomics of Patient-Derived Xenografts: A Strategy to Discover Tumor-Associated Proteins in High-Grade Serous Ovarian Cancer

Cell Syst. 2019 Apr 24;8(4):345-351.e4. doi: 10.1016/j.cels.2019.03.011. Epub 2019 Apr 10.


High-grade serous ovarian carcinoma (HGSC) is the most common and lethal subtype of gynecologic malignancy in women. The current standard of treatment combines cytoreductive surgery and chemotherapy. Despite the efficacy of initial treatment, most patients develop cancer recurrence, and 70% of patients die within 5 years of initial diagnosis. CA125 is the current FDA-approved biomarker used in the clinic to monitor response to treatment and recurrence, but its impact on patient survival is limited. New strategies for the discovery of HGSC biomarkers are urgently needed. Here, we describe a proteomics strategy to detect tumor-associated proteins in serum of HGSC patient-derived xenograft models. We demonstrate proof-of-concept applicability using two independent, longitudinal serum cohorts from HGSC patients.

Keywords: N-glycosylation; biomarker; ovarian cancer; patient-derived xenograft; serum proteomics; targeted proteomics.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Biomarkers, Tumor / blood*
  • Carcinoma / blood*
  • Carcinoma / pathology
  • Cell Line, Tumor
  • Female
  • Glycomics / methods
  • Glycoproteins / blood*
  • Humans
  • Mice
  • Mice, Inbred NOD
  • Mice, SCID
  • Ovarian Neoplasms / blood*
  • Ovarian Neoplasms / pathology
  • Proteomics / methods*


  • Biomarkers, Tumor
  • Glycoproteins